-
August 2, 2023 Lupin Receives Approval from U.S. FDA for Fluocinolone Acetonide Topical Oil
-
August 1, 2023 Lupin Receives Approval from US FDA for Turqoz® (Norgestrel and Ethinyl Estradiol Tablets USP)
-
July 28, 2023 Lupin Foundation Strengthens Lives Program With Its First Mobile Medical Van ; Flag-Off by Health Minister, Government Of Rajasthan
-
July 27, 2023 Lupin Announces Resolution of USFDA Warning Letter for its Goa and Pithampur Facilities
-
July 26, 2023 Lupin Receives Approval from TGA Australia for Tiotropium Dry Powder for Inhaler for Treatment of COPD
-
July 24, 2023 Lupin Digital Health and The American College of Cardiology Announce First-Of-Its-Kind Collaboration to Revolutionize In-home Cardiovascular Care in India with Digital Therapeutics
-
July 21, 2023 Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets
-
July 21, 2023 Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment in Germany
-
July 14, 2023 Lupin Receives Approval from U.S. FDA for Chlorpromazine Hydrochloride Tablets USP
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications